Effect of recombinant PDGF-BB on bone formation in the presence of β-tricalcium phosphate and bovine bone mineral matrix: a pilot study in rat calvarial defects. by Luvizuto, Eloá R et al.
RESEARCH ARTICLE Open Access
Effect of recombinant PDGF-BB on bone
formation in the presence of β-tricalcium
phosphate and bovine bone mineral
matrix: a pilot study in rat calvarial defects
Eloá R. Luvizuto1, Stefan Tangl2,3, Toni Dobsak2,3, Karoline Reich2,3, Reinhard Gruber4,5*, Celso K. Sonoda1
and Roberta Okamoto6
Abstract
Background: Supplementation of bone substitutes with recombinant platelet-derived growth factor-BB (PDGF-BB)
can enhance bone regeneration. The aim of the study was to evaluate the effect of PDGF-BB on bone formation in
the presence of β-tricalcium phosphate and bovine bone mineral matrix in a rat calvaria defect model.
Methods: The authors examined 5 mm rat calvarial defects treated with β-tricalcium phosphate (TCP) or
demineralized bovine bone mineral (DBBM) with and without 0.3 mg/ml recombinant PDGF-BB. Calvaria defects
were randomly divided into the following treatment groups (n = 5); TCP; TCP plus PDGF-BB; DBBM; DBBM plus
PDGF-BB; and untreated empty control. After 45 days, bone formation was evaluated by histomorphometry and
fluorescence microscopy.
Results: The authors report that the area of newly formed bone was similar between the empty controls and the
two bone substitutes, TCP and DBBM. Supplementation of TCP and DBBM with PDGF-BB had no significant impact
on bone formation. Fluorochrome staining revealed no visible changes in the pattern of bone formation in defects
filled with TCP and DBBM, irrespective of PDGF-BB. Furthermore, supplementation with PDGF-BB did not influence
biomaterial degradation.
Conclusions: The authors concluded that PDGF-BB had no impact on bone formation and degradation of
bone substitutes in the respective rodent models. Thus, possible beneficial effects of PDGF-BB may require
other model situations.
Keywords: Bone substitutes, Bone formation, Bone regeneration, Bone augmentation, Platelet-derived growth
factor-BB, Rat calvaria defects, β-tricalcium phosphate, Demineralized bovine bone mineral, Histomorphometry,
Graft consolidation
Background
Biomaterials can be supplemented with growth factors
to enhance the natural process of bone formation [1].
Bone formation is part of a sequential process initiated
by a blood clot that is formed and organized into a
granulation tissue before woven bone spans the defect
space [2]. Woven bone provides a scaffold for parallel-
fibred bone deposition, and finally bone remodeling
dominates the scene, resulting in lamellar bone. Recom-
binant platelet-derived growth factor-BB (PDGF-BB) can
support the process of bone formation, presumably by
serving as a mitogen and chemoattractant for mesenchy-
mal cells and by stimulating inflammatory cells such as
macrophages to secrete growth factors [3–5]. This con-
cept has led to a series of preclinical and clinical studies
on the beneficial effects of PDGF-BB when combined
with bone substitutes that provide a surface for the
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newly formed bone to grow from the edges into the
center of the defect.
Preclinical studies have suggested that PDGF-BB in
combination with deproteinized bovine and equine bone
blocks can regenerate significant amounts of bone in se-
vere mandibular ridge defects [6, 7]. Similar approaches
have shown that PDGF-BB can accelerate fracture heal-
ing in geriatric osteoporotic [8] and diabetic rats [9], and
enhance healing after bone distraction [10]. Thus, there
is accumulating evidence from preclinical research that
PDGF-BB can support bone formation. From a clinical
perspective, the FDA has approved the combination of
PDGF-BB and β-tricalcium phosphate (TCP) for the
treatment of periodontal defects (GEM21S®) [11].
Moreover, locally administered PDGF-BB and TCP
(Augment®) have been investigated in acute wrist
fractures [12] and proved to support hindfoot and ankle
fusions [13]. Thus, supplementation of TCP with PDGF-
BB is a favorable strategy in regenerative dentistry,
orthopedics and traumatology.
Critical-size rat calvarial defect models have been
used to test PDGF-BB together with a chitosan carrier
[14, 15]. However, whether TCP and demineralized
bovine bone mineral (DBBM) supplementation with
PDGF-BB is capable of overcoming the weak osteogenic
potential of the rat calvarium remains to be tested. The
aim of this pilot study was to evaluate the effect of PDGF-
BB on bone formation in rat calvarial defects augmented
with TCP or DBBM after 45 days, by means of histomor-
phometry and fluorescence microscopy.
Methods
Study design and ethics
Twenty-five Wistar rats (90 days old), acquired from the
Animal Center of São Paulo State University were main-
tained at a temperature of 22 °C in a 12-h light/ 12-h
dark cycle with free access to water and rodent food. A
total of 25 calvarial defects (5-mm-diameter, one defect
per animal) were randomly divided into 5 treatment
groups, with a total of 5 defects per treatment group
(n = 5). The treatment groups were as follows: [1]
500–1000 μm β-tricalcium phosphate (TCP) (Cerasorb®M,
Curassan Ltd, Germany); [2] TCP plus 0.3 mg/ml of
rPDGF-BB (R&D Systems, Inc., Minneapolis, MN, USA);
[3] 250–1000 μm demineralized bovine bone mineral
matrix (DBBM) (0.25 mm-1 mm Bio-Oss®, Geistlich
Pharma Group Ltd, Wolhusen, Switzerland); [4] DBBM
plus PDGF-BB; and [5] an untreated empty control (EC).
The present study complied with the principles of labora-
tory animal care and national laws on animal use, and the
study was authorized by the Animal Research Ethics
Committee of the Araçatuba Dental School, UNESP-
Univ Estadual Paulista, São Paulo, Brazil (protocol #
02402–2012).
Surgical procedures and fluorochrome labeling
After general anesthesia with xylazine (0.03 ml/100 g body
weight [bw]/intraperitoneal [ip]; Dopaser® Laboratories
Calier SA, Barcelona, Spain) and ketamine (7 ml/kg bw/ip;
Fort Dodge Saúde Animal Ltd, Brazil), the animal skulls
were shaved and disinfected with polyvinylpyrrolidone
iodide (Indústria Química e Farmacêutica Rioquímica Ltd,
Brazil). By using an aseptic technique, an incision was
made through the skin of the calvaria and periosteum, and
full-thickness flaps were reflected. Under copious sterile
saline irrigation, one 5-mm-diameter bone defect was pre-
pared with a trephine bur (3i Implant Innovations, Inc.,
Palm Beach Gardens, USA) in each animal. The defect
was treated as described above before the periosteum was
repositioned and sutured with polylactic acid sutures
(Vycril 5.0, Ethicon, Johnson Prod., São José dos Campos,
Brazil). The skin was closed with nylon sutures (Nylon
5.0, Mononylon, Ethicon). All animals received a single
dose of 20.000 UI of penicillin G benzathine (Pentabiótico,
Veterinário Pequeno Porte, Fort Dodge Saúde Animal
Ltd, Campinas, Brazil) by intramuscular injection. Rats
received 20 mg/kg body weight of calcein and alizarin –
soluble in saline solution - (Sigma Chemical, St. Louis,
MO, USA) by intramuscular injection on the 15th
and 30 th postoperative day, respectively. The rats
were euthanized by anesthetic overdose after the 45th
postoperative day.
Sample processing and histomorphometric analysis
The relevant part of the skull was removed and fixed in
neutral buffered 4 % formalin solution. The samples
were dehydrated in ascending grades of alcohol and
embedded in light-curing resin (Technovit 7200 VLC +
BPO, Kulzer & Co., Hanau, Germany). The blocks were
processed with the Exakt Cutting and Grinding Equip-
ment (Exakt Apparatebau, Norderstedt, Germany) in ac-
cordance with a standardized method [16]. Sections
were prepared parallel to the sagittal suture through the
center of the defect and reduced to a thickness of
approximately 40 μm before being stained with Levai-
Laczko dye. One sample per animal, the centermost
section, was subjected to blinded histomorphometric
analyses. Stained sections were examined by light
microscopy, and digital images were captured with the
Olympus DotSlide system 2.4 (Olympus, Tokyo, Japan).
Single pictures were assembled and stitched to one
another to generate large overview images with a reso-
lution of 3117 pxl/mm. For the final histomorphometric
evaluation this initial resolution was reduced to 1559
pxl/mm. A set of rules for the classification of bone and
bone substitute materials was created with the Definiens
Developer XD 2.1 software (Definiens, Munich, Germany)
based on color and morphological differences and the
results were manually controlled and corrected in the
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Photoshop program (Adobe Photoshop, Adobe, San Jose,
CA, USA). Analysis was restricted to the gap region (TAr)
between the two edges of the drilled hole. With the histo-
morphometry software (Definiens Developer XD 2.1,
Munich, Germany) the areas of newly formed bone
(nBAr) and bone substitute material (BSAr) were
measured in mm2. From these primary measurements the
percentages of newly formed bone (nBAr/TAr) and bone
substitute material (BSAr/TAr) within the total region of
interest (TAr) were calculated. Qualitative fluorochrome
analyses were performed with use of the epifluorescence
mode of a Nikon Microphot-FXA microscope (Nikon,
Tokyo, Japan).
Statistics
Data were analyzed by using permutation tests based on
t-tests; p-values were adjusted for multiple testing by
means of the step-down minP procedure. Significant
difference was assigned at the level of p < 0.05. The R
version 3.1.0 (R Core Team 2013) program was used for
computations and graphs were created by means of the
ggplot2 program.
Results
Clinical observations
No animals and no samples were lost during the experi-
ment. In general, post-surgical healing was uneventful.
Fig. 1 Histological images of treated and untreated rat calvarial defects at 45 days post-surgery: Representative images indicated partially healed
defects, bridged by a conglomerate of biomaterial and new bone tissue for treated groups (TCP, TCP + PDGF, DBBM, DBBM+ PDGF, Empty Control)
(Levai-Laczko stain). New bone formation was mostly restricted to areas close to the original borders of defects in the control group. No substantial
bone formation was observed in empty defects, only a thin layer of fibrous soft tissue separated the defect area from the underlying brain tissue. The
empty control showed most of the defects occupied by connective tissue composed of large numbers of collagen fibers parallel to the wound defect.
The defect sites that were originally treated with TCP and DBBM were partially bridged (arrow) by a conglomerate of biomaterial and new bone tissue.
Immature osseous islands were also observed
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Qualitative and quantitative histology
As indicated in Fig. 1, no complete defect closure was
observed in the histological specimens. No substantial
bone formation was observed in empty defects; only a
thin layer of fibrous soft tissue separated the defect area
from the underlying brain tissue. New bone formation
was mostly restricted to areas close to the original
borders of defects in the control group. In empty
controls, connective tissue composed of large numbers
of collagen fibers parallel to the wound defect dominated
the scene. The connective tissue in the central part of
the defect was thinner than that in the original calvar-
ium. Also noticeable in Fig. 1 were defect sites that were
originally treated with TCP and DBBM; these were par-
tially bridged by a conglomerate of biomaterial and new
bone tissue. Immature osseous islands were occasionally
observed. Remnants of TCP and DBBM were visible and
in intimate contact with the bone tissue, especially at the
defect margins. A similar situation occurred when TCP
and DBBM were supplemented with PDGF-BB (Fig. 1).
There were no obvious signs of cellular inflammatory in-
filtrate or foreign body reaction in most of the sections.
A large portion of the graft particles remained un-
changed and maintained the defect space. At the defect
margins, new bone was laid onto the surface of TCP and
DBBM, indicating that both biomaterials were biocom-
patible and osteoconductive.
Histomorphometric analysis showed that nBAr at the
defect site, and when normalized for the overall defect
area (TAr), did not differ significantly among the five
groups. Similarly, the residual amount of bone substi-
tutes (BSAr) was not affected by supplementation with
PDGF-BB (Fig. 2).
Fluorescence staining
The distribution of green and red staining indicated
bone formation between day 15 and day 30 post-
surgery, irrespective of the biomaterial used (Fig. 3).
Fluorochrome images at higher magnification support
the histological findings; dark red staining in histo-
logical samples also emitted strong green and red
fluorochrome signals. Bone formation (as indicated by
green and red staining) occurred throughout the de-
fects filled with TCP and DBBM, irrespective of the
presence of PDGF-BB. Empty control showed only
weak staining.
Discussion
The key finding of the present study was that PDGF-BB
had no impact on bone formation or the degradation of
the two bone substitutes in rat calvarial defects at 45 days
of defect healing. Consistent with these findings, PDGF-
BB loaded onto TCP had no effect on new bone forma-
tion after 8 weeks in the rat calvarial defect model [17].
Fig. 2 Histomorphometric analysis of the defect region. Area of newly formed bone in mm2 (nBAr); percentage of newly formed bone (nBAr/TAr);
area of the remaining bone substitute material in mm2 (BSAr); percentage of bone substitute material (BSAr/TAr)
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Furthermore, PDGF-BB combined with DBBM failed to
improve bone formation after 3 and 5 months [18].
PDGF-BB in combination with allografts did not signifi-
cantly increase bone formation in supracrestal defects in
dog mandibles after 8 weeks [19]. The findings of the
present study are also consistent with previous studies
showing that PDGF-BB had limited impact on deg-
radation of TCP particles over 4 weeks [20] and
8 weeks [17]. Although the majority of studies have
found beneficial effects of PDGF-BB during bone re-
generation [3, 8–11, 20, 21], it should be borne in
mind that as yet, there are no clearly defined vari-
ables that predict the beneficial effects of PDGF-BB
on bone regeneration.
The authors could speculate that the osteogenic cap-
acity of rat calvarial defects is weak, probably because of
the thin calvaria that is the origin of new bone. In
support of this theory are the authors’ data showing no
differences in the biomaterial residues between TCP and
DBBM. These data were also unexpected because DBBM
has a considerably slower degradation profile compared
with TCP. Once again, the low turnover situation in rat
calvarial defects may hold an explanation for this obser-
vation. Overall, bone healing for all groups was limited
in this study, compared with other studies conducted
with similar observation periods [16]. This low turnover
situation was supported by the fluorescence staining re-
sults at 15 and 30 days post-surgery that were consistent
Fig. 3 Fluorescence staining of treated and untreated rat calvaria defects: In agreement with the bright-field microscopic findings, bone formation,
exhibiting green and red staining, was tenuous and occurred throughout the defects filled with TCP and DBBM, irrespective of the presence of
PDGF-BB. No effects of PDGF-BB supplementation were observed. Empty control defects showed only weak staining that was also congruent with
bright-field microscopy. These detailed analyses provided deeper insight into the osteoconductive properties of TCP and DBBM and the lack of visible
changes after the addition of PDGF-BB
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with the histological observation of bone formation,
again without visible changes arising from the addition
of PDGF-BB. This low turnover situation is a possible
explanation why the expected beneficial effects of
PDGF-BB on bone regeneration failed in the present
study. The rat calvarial defect model may perhaps not be
ideal for studying the impact of PDGF-BB on bone for-
mation in the presence of bone substitutes.
Conclusions
In the pilot study, PDGF-BB loaded onto TCP or DBBM
had no beneficial effect on new bone formation after
45 days in the rat calvarial defect model.
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